French biopharmaceutical company Ipsen has agreed to acquire Memo Therapeutics in a transaction valued at over €700 million, according to separate reports that cite the deal at more than $799 million depending on currency conversion. The acquisition is described as a significant step for Ipsen’s growth strategy and is expected to expand its pipeline and capabilities through Memo Therapeutics’ assets. Both outlets frame the announcement as a deal of substantial size for the companies involved, with the valuation presented in different currencies. Details on payment structure, timing, regulatory approvals, and expected closing date are not provided in the provided source text. The reports indicate that the acquisition terms place a total value above the stated thresholds, but they do not outline specific operational changes or changes to management. Overall, the coverage is consistent on the core facts: Ipsen is buying Memo Therapeutics, and the agreed value is over €700 million (or over $799 million).